News from amgen A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 22, 2019, 02:00 ET Amgen announces a recommended public cash offer to the shareholders of Nuevolution

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be...


May 21, 2019, 16:00 ET Amgen Announces Voting Results Of Annual Meeting Of Stockholders

Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately...


May 16, 2019, 16:00 ET Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on...


May 15, 2019, 17:07 ET Amgen Showcases Oncology Pipeline At ASCO 2019

Amgen (NASDAQ: AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of...


May 10, 2019, 16:00 ET Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference

Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019. David W....


May 02, 2019, 16:30 ET Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting

Amgen (NASDAQ:AMGN) today announced that it will present new long-term data of Aimovig® (erenumab-aooe) across the migraine spectrum at the 2019...


May 02, 2019, 16:00 ET Amgen And Syapse Enter Precision Medicine Collaboration In Oncology

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, ...


May 01, 2019, 16:00 ET Amgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer

Amgen (NASDAQ:AMGN) today launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in...


Apr 30, 2019, 16:01 ET Amgen Reports First Quarter 2019 Financial Results

Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2019. Key results include: Total revenues were unchanged at $5.6...


Apr 25, 2019, 16:00 ET Amgen Announces Webcast of 2019 First Quarter Financial Results

Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 30, 2019, after the close of the U.S....


Apr 17, 2019, 16:00 ET Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida

The Amgen Foundation, together with the University of South Florida (USF), today announced the launch of the Amgen Biotech Experience (ABE) program...


Apr 15, 2019, 16:00 ET EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved...


Apr 09, 2019, 15:57 ET FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™...


Apr 07, 2019, 05:00 ET Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe

Amgen (NASDAQ:AMGN) today announced new data presented from a cross-sectional study revealing a gap in the diagnosis and treatment of osteoporosis in ...


Mar 20, 2019, 08:30 ET Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF...


Mar 15, 2019, 16:00 ET Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke

Amgen (NASDAQ:AMGN) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha® (evolocumab) which will...


Mar 12, 2019, 09:29 ET Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk

Amgen (NASDAQ:AMGN) today launched Cholesterol 911, a national initiative urging high-risk cardiovascular disease patients to reduce their risk of...


Mar 07, 2019, 16:05 ET Amgen Announces 2019 Second Quarter Dividend

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. The dividend will ...


Mar 07, 2019, 16:00 ET Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019, in Boston....


Mar 06, 2019, 16:00 ET New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations

Amgen (NASDAQ:AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from ...


Feb 28, 2019, 16:00 ET Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019

Amgen (NASDAQ:AMGN) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer...


Feb 25, 2019, 16:56 ET Jury Upholds Amgen's Patents On Repatha® (evolocumab)

Amgen (NASDAQ:AMGN) today announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to...


Feb 21, 2019, 08:30 ET Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance...


Jan 29, 2019, 16:01 ET Amgen Reports Fourth Quarter And Full Year 2018 Financial Results

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key...


Jan 24, 2019, 16:30 ET Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results

Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2018 financial results on Tuesday, Jan. 29, 2019, after the...